Zheng Xiaoyu, the former chief of the State Food and Drug Administration
(FDA), who was accused of taking bribes and stripped of power in 2005, will face
an initial court hearing on Tuesday.
The No 1 Intermediate
People's Court in Beijing will try Zheng alongside his former secretary Cao
Wenzhuang on charges that they conspired to take bribes, Gao Zicheng, Cao's
lawyer, told China Daily yesterday.
Gao said that Zheng stands accused of bribe taking and severe dereliction of
An investigation conducted last month by the CPC Central Commission for
Discipline Inspection accused Zheng of taking bribes totaling more than 5
million yuan (about $650,000).
In the same investigation, Cao was accused of taking bribes totaling 2
Sources with the court said the trial of Zheng and Cao will be conducted in
camera and that a verdict is unlikely to be reached before June.
China Business News said that 31 people are alleged to be involved in the
corruption scandal, with several of them holding senior positions within the
Zheng's wife Liu Naixue and son Zheng Hairong, plus a number of drug
companies were also investigated.
One firm that was named was the Kongliyuan Group from South China's Hainan Province, which is alleged to have bribed Zheng in
return for FDA approvals on 277 medicines, most of which were antibiotics that
yield high profits.
head of the company has been detained pending further investigation.
Zheng, 63, was removed from his post in June 2005. In December 2006, he was
accused of taking bribes during his eight years as head of the top drug
The CPC Central Commission for Discipline Inspection, the country's foremost
disciplinary department, began investigating the case in December.
Cao Wenzhuang, the former director of the administration's drug registration
department, also came under investigation last year.
In November, Hao Heping, the former director of the administration's medical
equipment department, was sentenced to 15 years in prison for accepting bribes.
Both Hao and Cao had previously worked as Zheng's secretary and held power
over approving new medicines or medical equipment.
Amid a slew of graft cases, the administration has made efforts to clean its
own house with the introduction this year of a series of anti-corruption
measures and regulations.
(For more biz stories, please visit Industry Updates)